L&C BIOLTD Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for L&C BIOLTD.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth82.2%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

There's No Escaping L&C BIO Co.,LTD's (KOSDAQ:290650) Muted Revenues Despite A 30% Share Price Rise

Dec 14
There's No Escaping L&C BIO Co.,LTD's (KOSDAQ:290650) Muted Revenues Despite A 30% Share Price Rise

Is L&C BIOLTD (KOSDAQ:290650) A Risky Investment?

Nov 12
Is L&C BIOLTD (KOSDAQ:290650) A Risky Investment?

Here's Why L&C BIOLTD (KOSDAQ:290650) Has A Meaningful Debt Burden

Aug 06
Here's Why L&C BIOLTD (KOSDAQ:290650) Has A Meaningful Debt Burden

What L&C BIO Co.,LTD's (KOSDAQ:290650) 27% Share Price Gain Is Not Telling You

Jul 05
What L&C BIO Co.,LTD's (KOSDAQ:290650) 27% Share Price Gain Is Not Telling You

L&C Bio's (KOSDAQ:290650) Performance Raises Some Questions

Mar 27
L&C Bio's (KOSDAQ:290650) Performance Raises Some Questions

Does L&C Bio (KOSDAQ:290650) Deserve A Spot On Your Watchlist?

Apr 20
Does L&C Bio (KOSDAQ:290650) Deserve A Spot On Your Watchlist?

L&C Bio's (KOSDAQ:290650) Earnings Are Of Questionable Quality

Apr 01
L&C Bio's (KOSDAQ:290650) Earnings Are Of Questionable Quality

Is L&C Bio (KOSDAQ:290650) A Risky Investment?

Mar 02
Is L&C Bio (KOSDAQ:290650) A Risky Investment?

Announcing: L&C Bio (KOSDAQ:290650) Stock Increased An Energizing 163% In The Last Year

Feb 03
Announcing: L&C Bio (KOSDAQ:290650) Stock Increased An Energizing 163% In The Last Year

What Is The Ownership Structure Like For L&C Bio Co., Ltd (KOSDAQ:290650)?

Jan 04
What Is The Ownership Structure Like For L&C Bio Co., Ltd (KOSDAQ:290650)?

Should You Be Excited About L&C Bio Co., Ltd's (KOSDAQ:290650) 16% Return On Equity?

Dec 08
Should You Be Excited About L&C Bio Co., Ltd's (KOSDAQ:290650) 16% Return On Equity?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as L&C BIOLTD has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

KOSDAQ:A290650 - Analysts future estimates and past financials data (KRW Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/202470,031-5,961-42,845-15,715N/A
6/30/202472,04349,008-39,492-15,002N/A
3/31/202470,63549,313-32,927-8,488N/A
12/31/202368,87048,361-37,057-12,133N/A
9/30/202367,48753,593-10,164-5,401N/A
6/30/202359,7164,114-28,029-6,684N/A
3/31/202356,3703,882-43,417-10,237N/A
12/31/202252,5724,544-43,594-6,076N/A
9/30/202250,39911,092-43,263-5,744N/A
6/30/202249,55312,530-20,9223,186N/A
3/31/202247,10113,176-2,82510,715N/A
12/31/202145,67713,814-48110,907N/A
9/30/202141,57911,0211,36913,245N/A
6/30/202137,95611,1468639,259N/A
3/31/202135,14111,1072,7678,296N/A
12/31/202032,97310,8134,3647,419N/A
9/30/202031,8687,2135,0407,791N/A
6/30/202030,4106,9784,6887,465N/A
3/31/202030,3337,2884,0766,519N/A
12/31/201929,1527,2504,4226,431N/A
9/30/201927,3486,5053,0914,503N/A
6/30/201924,9785,8602,1053,539N/A
3/31/201922,6245,5211,0463,404N/A
12/31/201821,2415,208-9223,846N/A
9/30/201819,6185,1861024,303N/A
6/30/201819,9665,396N/A5,019N/A
3/31/201818,6314,345N/A4,937N/A
12/31/201717,9013,753N/A3,818N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if A290650's forecast earnings growth is above the savings rate (2.7%).

Earnings vs Market: Insufficient data to determine if A290650's earnings are forecast to grow faster than the KR market

High Growth Earnings: Insufficient data to determine if A290650's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if A290650's revenue is forecast to grow faster than the KR market.

High Growth Revenue: Insufficient data to determine if A290650's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if A290650's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 18:48
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

L&C BIO Co.,LTD is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kyung-rae HanDaishin Securities Co. Ltd.
Jongsun ParkEugene Investment & Securities Co Ltd.
Min-jung KwagHyundai Motor Securities Co. Ltd.